A phase I-IIa dose-ranging study of pemetrexed (Alimta) plus cetuximab (Erbitux) in patients with recurrent non-small cell lung cancer (NSCLC): Hoosier Oncology Group LUN04-79
Phase of Trial: Phase I/II
Latest Information Update: 04 Oct 2016
At a glance
- Drugs Cetuximab (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 08 Nov 2007 Status changed from in progress to completed as reported by ClinicalTrials.gov.
- 27 Nov 2005 New trial record.